Tailwind AI logo

Bring Your Paper Records Into the Digital Age — Without an MES

Advisory support for pharmaceutical manufacturers evaluating historical-record digitization, data integrity, and oversight across contract partners—without assuming a full MES replacement.

Built for the Realities of GMP Manufacturing

Whether you run your own site or oversee a network of contract manufacturers, the platform meets you where your data lives today.

Paper to Digital, Without an MES

Assess how handwritten batch records, logbooks, and QA forms can move into a controlled digital workflow without assuming a full MES replacement.

ALCOA+ Data Integrity

Define validation, review, traceability, and governance controls around the Attributable, Legible, Contemporaneous, Original, and Accurate principles.

Contract Manufacturing Oversight

Evaluate oversight needs across CDMOs, CMOs, and sites when partners use different MES, LIMS, and document systems.

A Data Fabric For Compliance and Oversight

A practical framework for evaluating record conversion, review controls, traceability, and the human decisions required to maintain defensible data.

Document extraction assessment

Assess where document extraction could support batch records, logbooks, and QA forms, and where verified human review remains necessary.

Rule-based review concepts

Explore how defined rules may help identify exceptions for review without presenting software as a virtual Quality Unit.

Human + AI Workflows

Technology may assist with triage and organization; the designated Quality Unit retains review, approval, and disposition responsibility.

Explainable & Traceable

Traceability to source pages, signatures, and timestamps should be designed and validated as part of any implementation.

Oversight Concept

A Watchdog for Your Manufacturing Operations

An advisory framework for assessing how data from internal systems and contract manufacturers could support more focused, risk-based quality oversight. Capabilities depend on the client’s validated systems, controls, and implementation.

Data-source assessment

Map relevant MES, LIMS, historian, and partner-system sources before selecting an integration or oversight approach.

Exception and trend rules

Define risk-based rules for surfacing potential trends, deviations, and exceptions for qualified review.

Risk-based review design

Identify where structured review may focus human attention while preserving required checks, approvals, and oversight.

Multi-site and CDMO governance

Establish common data definitions, escalation criteria, and governance expectations across internal sites and contract partners.

When You Need It Most

High-volume batch releases with tight timelines
Remote oversight of multiple CDMO partners
Pre-approval inspection readiness campaigns
Cell & gene therapy supply chain complexity
Post-deviation remediation and enhanced monitoring
Sterile fill-finish environmental monitoring

Where It Delivers Value

CDMO / CMO batch record oversight across multiple sponsors
Digitizing legacy paper batch records and logbooks
Deviation and CAPA trend analysis across sites
Pre-inspection readiness and mock FDA audits
Cell & gene therapy contract manufacturing traceability
Sterile fill-finish investigation acceleration

Evaluating How to Modernize Records and Oversight?

Get a walkthrough tailored to your operation — whether you're digitizing a decade of paper batch records or unifying oversight across multiple CDMOs.

Get In Touch